A T-Cell Epitope-Based Multi-Epitope Vaccine Designed Using Human HLA Specific T Cell Epitopes Induces Sterile Immunity against Experimental Visceral Leishmaniasis in Hamsters

Aryandra Arya and Sunil K Arora*

Molecular Immunology, Department of Immunopathology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India
* Correspondence: arora.sunilkumar@pgimer.edu.in

Abstract: Visceral Leishmaniasis is a neglected tropical disease affecting 12 million people annually. Even in the second decade of the 21st century, it has remained without an effective vaccine for human use. In the current study, we have designed three multiepitope vaccine candidates by the selection of multiple IFN-γ inducing MHC-I and MHC-II binder T-cell specific epitopes from 3 previously identified antigen genes of Leishmania donovani from our lab, by immune-informatic approach using IFNepitope, NET-MHC-1 and NET MHC-2 webservers. We have tested the protective potential of these three multiepitope proteins as vaccine in a hamster model of visceral leishmaniasis. The immunization data revealed that the vaccine candidates induced a very high level of Th1 biased protective immune response in vivo in a hamster model of experimental visceral Leishmaniasis, with one of the candidates inducing a sterile immunity. The vaccinated animals displayed highly activated monocyte macrophages with the capability of clearing intracellular parasites due to increased respiratory burst. Additionally, these proteins induced activation of polyfunctional T cells secreting INF-γ, TNF-α, and IL-2 in ex-vivo stimulation of human peripheral blood mononuclear cells, further supporting the protective nature of designed candidates.

Keywords: Leishmania; Vaccine; T cell; Epitopes; Hamster; IFN-γ epitope; Sterile Immunity

Introduction

After 100 years of discovery, Visceral Leishmaniasis (VL) remains elusive to a vaccine candidate for humans. The development of a vaccine for kala-azar has manifested itself into an immunological challenge of its own [1]. According to WHO estimates, annually 12 million new cases are being registered worldwide [2,3]. VL is a systemic infection of the reticuloendothelial system with macrophages being the primary host, if left untreated the condition easily becomes perilous. The immunology of the disease is centered around the Th1 cytokine axis[4]. In the natural course of infection, there is polyclonal hypergammoglobinemia with non-specific antibody response along with elevated levels of immunosuppressive cytokines like IL-10 and TGF-β, while recovering patients develop elevated levels of IFN-γ and TNF-α [5,6]. Acute infection in recovered patients results in lifelong immunity, which indicates that an effective vaccine is possible[7].

The efficacy of a T cell-based prophylactic vaccine for any infection depends upon multiple factors including primary signal generated through TCR (CD3 complex) and peptide conjugated major histocompatibility complex (MHC) molecules [8,9], while the secondary stimuli are based on coreceptor activation like CD80/86-CD28 [10]. Additionally, the generation of specific cytokine milieu affecting the outcome depends upon PAMP (Pathogen-associated molecular pattern), & Toll-like receptors (TLR) associated with Antigen-presenting cells(APC) like dendritic cells [8]. In the events leading to T cell activation, besides the role of T cell Receptor (TCR) and coreceptors, the role of a core epitope molecule is not completely understood [11]. Many theories have been proposed to account...
for antigen discrimination for T cell selectivity and sensitivity, but the extent of the role of epitope has remained unexplored [12–17]. In this regard, many researchers have categorized T cell epitopes as dominant and subdominant or optimal and suboptimal epitopes [18–22]. Dominant epitopes are strong binders of MHC molecules and create a strong signal when linked in an MHC-p-TCR complex [23,24]. Optimal epitopes and strong TCR signal strength have also been linked with Th1 immune profile generation specifically MHC-I epitopes [25–29].

In the past, many vaccine candidates have been proposed for VL, which either have utilized the whole parasite in attenuated form or complete antigenic protein [30]. Regarding novel vaccine candidates with a tailored response, immunoinformatic-predicted T cell-specific epitopes can be used to generate newer candidates [31,32]. Advancement in prediction models of linear and conformational epitopes has significantly boosted vaccine research in the last decades with the emergence of many epitope-based vaccine candidates for L. donovani, L. major and, L. infantum [33–39], and for other diseases [40–44]. Keeping in mind the immune-correlates of protection in Leishmania donovani infection, we have used the strategy of designing multiple vaccine candidates either by addition of various T cell epitopes in a single multi-epitope candidate or with the use of multiple IFN-γ inducing epitopes to generate different multi-epitope constructs. Three previously identified and tested indigenous vaccine candidates were selected as parent antigens for epitope mapping based on their IFN-γ inducive protective nature [45–47]. We have used various online servers like IEDB T cell epitope identification tools for MHC-I and MHC-II, NET MHC-1 & NET MHC-2 including ‘IFNepitope’ to map T cell epitopes [48]. T cell-stimulating nature of vaccine candidates was tested on healthy Human PBMC for Polymutational T cell activation along with IFN-γ, TNF-α, IL-2, and IL-10 cytokine generation, the results of which pointed towards the generation of polyfunctional T cells and strong IFN-γ and TNF-α responses. We selected the Syrian golden hamster as a disease model for protective efficacy evaluation in-vivo. Syrian golden hamster makes a good disease model for visceral leishmaniasis because the clinical features are similar to humans and the animals succumb to the disease in 10-12 weeks if not treated [49]. The protective potential and immunogenicity data in immunized hamsters revealed a very high level of protective efficacy against a virulent challenge along with induction of a strong Th-1 biased immune response.

Material and Methods

The study protocol was approved by Institutional Ethics Committee (IEC) of Post Graduate Institute of Medical Education & Research (PGIMER) Chandigarh India on August 8, 2016 vide ref. No. MK/2867/PhD/7754. And also by the Institute Animal Ethics Committee of PGIMER, Chandigarh, India on 13th Dec, 2016 vide Ref No. 85/IAEC/559.

Epitope Identification and Multiepitope candidate designing

Three novel antigen genes of Leishmania donovani, A2/1(AY-377788), B4/1 (AY-161269), and F2/1(AY-180912), were selected for epitope mapping [45]. We identified T cell epitopes using 3 different web servers, IEDB T cell epitope identification tools for MHC-I and MHC-II, NET MHC-1[50,51], NET MHC-2 [52], & IFNepitope [48].

For IEDB web server-based MHC-I T cell epitope identification tool, the query was submitted in FASTA format for all three genes. Other parameters were set at default. For each gene following MHC-I alleles were selected: HLA:A01, HLA:A02, HLA:A03, HLA:A24, HLB:B07, HLB:B08, HLB:B27, HLB:B39, HLB:B44, HLB:B58, HLAC:C04 & HLAC:C06 to maximize the population coverage. Similarly, for MHC-II specific T cell epitopes following MHC-II alleles were selected for each gene, DP1 DP2, DQ7, DR4, DRB1, DRB3, DRB5, and main DQ. The parameters were set at default values. All the results were downloaded in .XLS format. Epitopes were selected based on IC50 values of <50nM.
For NETMHC-1 4.0 input sequence was given in FASTA format, with other parameters set at the default value. HLA allele selection was as following: HLA: A01, HLA: A02, HLA: A03, HLA: A24, HLA: A25, HLA: B07, HLA: B15, HLA: B27, HLA: B39, HLA: B40, and HLA: B58, similarly for NETMHC-2 4.0 MHC-II alleles selected were as following DP, DQ, DR4, DRB3, & Main-DR. The results were obtained in .XLS format. The selection was based on strong binders defined as having a %rank<0.5.

For IFNepitope the input sequences were submitted in FASTA format and parameter values were set at default. Since IFNepitope does not require HLA allele submission for epitope prediction, the predicted epitopes were checked for HLA alleles by Propred and Propred1 (MHC class 1 and class 2 binding peptide prediction servers respectively) later on [53,54].

Based on epitope mapping results, 3 different multiepitope candidate proteins were designed: (Table 1) (Supplementary Figure 1-4 and Supplementary Table 1)

**Construct 1:** The design was based on epitopes identified through NETMHC-1 and NETMHC-2 and IEDB T-cell epitope prediction servers for both MHC1 and MHC-II. For each HLA allele high-affinity epitopes (strong binder) with <50nM IC50 were selected from the IEDB epitope server, similarly epitopes with percent rank <0.5% were selected using NETMHC-I and NETMHC-II. Integration of results from both NETMHC-1&2 and IEDB for MHC-I and MHC-II gave large sequences or island regions containing multiple overlaps of partially overlapping epitopes. These regions of multiple epitopes were linked by diglycine (-G-G-) residues to provide optimum steric flexibility and avoid any scrambling of epitope sequences by additional amino acids from the linker sequence. The sequence order of epitopes was kept similar to their native sequential order as in the parent antigen molecule (Supplementary Figure 5).

**Construct 2:** The second construct was designed based on IFN-γ inducing MHC-I binders. All IFNepitope predicted IFN-γ epitopes were additionally screened for MHC-I affinity by Propred1. The final epitopes were IFN-γ inducing epitopes, able to bind CTL of specific HLA allele. Similar to Construct 1, the epitope-rich regions were kept in native order and linked by diglycine linker sequence (Supplementary Figure 6).

**Construct 3:** The third construct was designed based on the results of IFNepitope Propred, and NetChop3.0. Epitopes picked were IFN-γ inducers and contained multiple Propred2 binders were selected. The flanking N-terminal and C-terminal regions of the epitope sequences were selected based on NetChop3.0 predicted cleavage sites of proteasome complex [55,56], these native N-terminal and C-terminal sequences were used to link epitopes (Supplementary Figure 7).

**Molecular Cloning and Recombinant Protein Production**

For the production of multi-epitope vaccine candidate protein, the multi-epitope sequences were reverse translated into nucleotide sequence and obtained in pMAT cloning vectors through Gene Art (ThermoFisher USA). The construct sequences were sub-cloned into pQE30 expression vector (Qiagen GmbH, Hilden, Germany), and transformation was carried out in M15 E. coli for protein expression. Protein expression was carried at 37°C by induction with 0.1mM IPTG and the over-expressed protein was isolated from inclusion bodies by solubilizing in tris buffer (pH 8.0). Membrane-bound protein was repeatedly washed in a buffer containing Deoxycholic acid and Tris-HCl with EDTA and finally dissolved in 6M Guanidium HCL (GuHCl). The excess GuHCl was removed by overnight dialysis against double distilled water (ddH2O). The purified product was tested for endotoxin levels using Endotoxin detection kit (THG10-0250, Hi-Media, India), the levels were within acceptable range i.e., less than 0.25 EU. The final product was lyophilized, weighed, and stored at -20°C. The purified proteins were confirmed for their molecular weight by SDS-PAGE separation and western blot. Individual bands were visualized by staining with Horse-radish peroxidase (HRP) conjugated anti-histidine (poly-HIS) antibody. (Details available in supplementary data)

**Protective efficacy study In Hamster model of Experimental Visceral Leishmaniasis**
The protective efficacy of the multiepitope vaccine proteins was evaluated in a hamster (*Mesocricetus auratus*) model of VL. A total of 48 hamsters were divided into 6 groups. Different groups of animals were immunized intraperitoneally (i.p.) with 50 µg each of proteins expressed from construct 1 (64 kDa), construct 2 (36 kDa), and construct 3 (29 kDa), admixed 1:1 (v/v) with Complete Freund’s adjuvant (CFA). The control groups of animals included an adjuvant control group, an unimmunized but infected group, and one healthy (unimmunized uninfected) group. Freund’s adjuvant was selected to generate a sustained and slow release of antigen [57,58]. The animals in vaccinated groups were given 2 booster doses of proteins i.p. at day 14 and 28 in emulsion form with Incomplete Freund’s adjuvant (IFA) [59]. (Details in supplementary table 4). Additionally, promastigotes for any *in vitro* challenge were obtained from an infected hamster by culturing the crushed spleen in RPMI-1640 culture media supplemented with 10% FBS and keeping at 25°C.

The hamsters were challenged with 1×10⁷ amastigotes (*Leishmania donovani* Dd8) intracardinally (i.c.) on day 42 post-immunization and were maintained in Animal Biosafety Level 2 (ABSL-2) cages for 60 days post-challenge before termination of the experiment. The immunization experiments with all three multi-epitope candidate proteins were repeated twice with a fresh batch of hamsters using the same immunization protocol.

Parasitological parameters

On the day of the termination of the experiment, the hamsters were euthanized in a sterile environment and the peritoneal cavity was dissected to reveal the spleen aseptically. The spleen was weighed and bisected into two halves such that a small portion from the middle was taken for touch impressions on a glass slide, while the other half of the spleen was used for splenic culture for viable parasite detection. The touch imprints were fixed with methanol and stained with Giemsa stain for 30-40 minutes. The stained touch impressions were analyzed for intracellular amastigotes under an oil immersion lens in an inverted bright field microscope (Olympus BX-51, Japan). The data were represented as Leishman Donovan units (LDU) calculated as Number of amastigotes/Number of Nucleated Cells × Weight of the organ(mg) (Bradley & Kiskley 1977).

Physical Parameters

Basic physical parameters of hamsters were analyzed in terms of body weight, spleen size, and spleen weight. Taken together these parameters were used to calculate splenic index which is spleen weight to whole body weight ratio multiplied by 100.

Spleen culture assay

The sterile portion of resected spleen from the euthanized hamsters was crushed to a single cell suspension in 2 ml RPMI-1640 medium (Sigma Aldrich, USA). Fifty µl of the suspension was used to inoculate 1 ml RPMI-1640 complete medium containing 10% Fetal bovine serum (FBS) (US origin, Gibco USA) and antibiotics (ampicillin & streptomycin) in a sterile culture tube. The cultures were incubated at 25°C in a BOD incubator and an aliquot was observed every alternate day for the development of promastigotes. The promastigote population was counted using a hemocytometer.

Immunological parameters

Macrophage Function Assays

The functional status of macrophages obtained from the peritoneum of experimental hamsters was assessed for intracellular parasite clearance and generation of the oxidative burst in terms of ROS production. For obtaining the macrophages, the peritoneal cavity of experimental hamsters was washed with a cold RPMI1640 culture medium before the removal of the spleen. The cells obtained from wash were seeded in a 24 well plate and
left for 6 hours at 37°C with 5% CO₂ in RPMI-1640 medium supplemented with 10% FBS. After 6 hours the cultures were agitated to remove the non-adherent cells and the culture media was replaced with fresh medium, leaving only adherent cells, mainly monocytes which differentiated into macrophages overnight, behind. For parasite clearance assay metacyclic promastigotes were obtained by isolating amastigotes from infected hamster spleen and cultivating them in blood agar slants overlaid with RPMI-1640 supplemented with 10% FBS at 25°C temperature. After promastigote formation metacyclic form was obtained by culturing the promastigotes for 7-9 days without changing the culture medium (M199, 10% FBS).

- **Parasite clearance**: To check the ability of macrophages to clear the intracellular parasites, the adherent macrophages (50,000 cells/well) were layered with live metacyclic CFSE-stained promastigotes in a 1:10 ratio and incubated at 34°C for 10 hours. The wells were washed to remove any uninternalized promastigotes. The cells were de-adhered using Trypsin EDTA solution, at specific time intervals of 12 hours, 24 hours & 48 hours, washed twice in cold sheath fluid, and acquired on a flow cytometer (FACs Calibur, BD Biosciences, USA) for CFSE signal. Quantitative assessment of internalized promastigotes was made in terms of Mean Fluorescence Intensity (MFI) at 12 hours, 24 hours & 48 hours. A decrease in MFI would indicate parasite clearance. The data analysis was done by BD CellQuest™ Pro software, by gating granulocytes and monocyte based on forward scatter (FSC) and side scatter (SSC) pattern. The baseline fluorescence was set based on uninfected unstained healthy cells.

- **Oxidative burst**: The capability of macrophages from the immunized hamsters for the production of reactive oxygen species (ROS) would indicate the restoration of normal function in terms of generation of oxidative burst. To assess that, 50,000 peritoneal adherent cells were cultured in a 24 well culture plate in presence of RPMI-1640 medium supplemented with 10% FBS. At the beginning of the culture, the cells were stimulated with bacterial lipopolysaccharide (LPS, 5 µg/ml) or 10 µg/ml of *Leishmania* Promastigote Soluble Antigen (LPSA). At 12 & 24 hours the cells were stained with 2',7’-dichlorofluorescein diacetate (DCFDA) for 35 minutes and acquired on a flow cytometer (BD FACS Calibur) for change in MFI due to ROS-mediated conversion of DCFDA to 2',7’-dichlorofluorescein (DCF). Post-acquisition analysis was done by BD CellQuest™ Pro and the baseline was set by unstimulated-stained cells.

**Post-immunization Immune-profiling**

To assess the type and quantum of immune-response generated post-immunization, the immunological parameters were analyzed from the spleen tissue by evaluating the gene expression of a set of immune-response related genes (List of genes selected for study- supplementary table 7) by real-time quantitative PCR. The RNA was isolated from splenic tissue using Trizol (Sigma) and cDNA was prepared using a first-strand synthesis kit (iScript cDNA Synthesis Kits, Bio-Rad USA). Primers for selected genes of interest were designed using Primer-BLAST (NCBI).

The RT qPCR was carried out on the LC480 platform (Roche diagnostics Nederland BV). The reaction parameters were set for an annealing temperature of 59°C for 60 seconds with a consecutive 45-second amplification step at 72°C. The amplification reaction was programmed for 37 cycles. The data was obtained in the form of cycle threshold (Ct) values. The expression levels were normalized to the reference gene (γ-Actin). The 2^ΔΔCt method was employed to calculate the relative expression of each gene. The ΔCT values were calculated using the formula: ΔCt = Ct (Gene of interest) – Ct (Reference gene), and then, ΔΔCt was calculated using the equation: ΔΔCt = ΔCt (Treated sample i.e., Immunized or Unimmunized animals) – ΔCt (Untreated sample i.e., Healthy uninfected animals), and final values were given in terms of fold change (2^ΔΔCt) to healthy control.
Polyfunctional T cell activation

Polyfunctional T cells are defined by their secretion of multiple cytokines at the same time. IFN-γ, TNF-α, and simultaneously IL-2 secreting T cells are directly correlated to protective response (41). To assess the capability of multiepitope protein constructs in inducing a polyfunctional T-cell response, the peripheral blood mononuclear cells (PBMC) from healthy human volunteers were stimulated in-vitro with 64 kDa, 36 kDa, 29 kDa proteins. Phorbol 12-myristate 13-acetate (PMA at 100 ng/ml) (Sigma Aldrich USA) along with 50 ng/ml ionomycin (Sigma Aldrich USA) and Phytohemagglutinin (PHA at 10µg/ml) (Sigma Aldrich USA) were used as control mitogen activators in separate wells. Total Leishmania promastigote soluble antigen (LPSA) at 20 µg/ml concentration was used as antigen control. At 14 hours post-stimulation, 5µg/ml Brefeldin A (BFA) (Sigma Aldrich USA) was added, and the cells were harvested after a further 2 hours incubation, washed with sterile PBS, and fixed with Cytoperm Cytofix buffer (BD Biosciences US). The cells were then stained with PE Mouse Anti-Human CD3 (552127, BD Biosciences US) for surface staining and with PE-Cy™7 Mouse Anti-Human IFN-γ (557643, BD Biosciences US), BV421 Mouse Anti-Human TNF (562783, BD Biosciences-US), FITC Mouse Anti-Human IL-2 (340448, BD Biosciences US) and APC Rat Anti-Human IL-10 (554707, BD Biosciences US) for intracellular cytokine staining. Finally, the cells were acquired on a flow cytometer (FACS CANTO, BD Biosciences -USA). The lymphocytes were gated based on the forward scatter (FSC) and side scatter (SSC) pattern. The gating and baseline settings were based on unstimulated-stained controls. Frequency of Triple positive (INF-γ +, TNF-α + & IL-2 +) and dual positive (INF-γ +, & TNF-α +) cells was calculated based on Boolean gating for INF-γ, TNFα & IL-2 triple-positive CD3+ T-cells, using FlowJo version 10.1 (Supplementary Figure 19, -22).

Statistical analysis

Statistical analysis was done on GraphPad Prism Version 6.0. Student’s T-test was employed to check the statistical difference between the two groups of treatments. P<0.05 was considered significant.

Results

Multiepitope vaccine designing

Three multiepitope constructs were designed utilizing the results obtained from the prediction tools. The first construct of molecular mass 64 kDa was based on the dominant epitopes of the high affinity for both MHC-I and MHC-II alleles. It included multiple overlapping epitopes from the regions aa 1-83 from B4/1(AY161269), aa 8-65, aa 77-206 from F2/1(AY180912) & aa 12-103, aa 125-223, aa 242-310, & aa 264-403 from A2/1(AY 377788). The second construct of 36 kDa mass was based on MHC-I (CTL) specific to the IFN-γ inducing epitope as predicted by IFNepitope and Propred1 results. A total number of 63 epitopes were used out of which 17 were dual binders for MHC-I and MHC-II alleles. The third construct of 29 kDa was designed using 24 epitopes positive for MHC-II alleles out of which 7 were also MHC-I(CTL) binders (Table 1).

Table 1. Multiple overlaying regions of epitopes used in designing of multiepitope constructs.

| Mass (kDa) | B4/1 (AY 161269) | F2/1 (AY 180912) | A2/1(AY 377788) |
|-----------|-----------------|-----------------|------------------|
| 1317 epitopes | aa 1-83 | aa 8-65 | aa 12-103 |
| | aa 77-206 | | |
| | aa 125-223 | aa 242-310 | |
| | aa 364-403 | | |
| 36 kDa | B4/1 (AY 161269) | F2/1 (AY 180912) | A2/1(AY 377788) |
| | aa 23-52 | aa 41-58 | aa 14-28 |
| | aa 69-89 | aa 186-196 | aa 46-70 |
| | aa 99-109 | aa 81-94 | |
| | | | aa 98-119 |
Multi-epitope construct proteins induced significant protection in the Hamster Model of Experimental Visceral Leishmaniasis

Survival efficacy: Post-challenge all the animals in all 3 immunized groups survived, while 2 animals in the un-immunized infection-alone group and 1 animal from the CFA-only group died due to disease-induced morbidity. Postmortem analysis revealed enlarged spleen with a high parasite burden.

Parasitological parameters and parasite load.

The animals from all the immunized groups resisted an increase in parasite burden as observed by a significantly lower parasite number (LDU) in spleen tissue touch imprints: 178 (± 47.03 SEM, p=0.0002) in 64 kDa immunized group, 332 (± 105.32 SEM, p=.0002) in 36 kDa immunized group and 478 (± 50.10 SEM, p=.0002) in 29 kDa immunized group, compared to 4277 (±661.1 SEM) and 4602 (±931.02 SEM) in unimmunized infected group and adjuvant control group respectively (Figures 1A, 1B & 2). The splenic index of immunized animals also corresponded with the parasite burden (Table 2).
Figure 1. A: Giemsa-stained touch impressions of spleen from different animal groups. a.1-3) Unimmunized infected animal, b.1-3) Complete Freund’s adjuvant (CFA) only, & c.1-3) healthy animal. Arrows indicating the infected cells. Magnification 10×100X (oil immersion) (Olympus Japan).
Figure 1. B: Giemsa-stained touch impressions of spleen from different animal groups. a.1-3) 29 kDa immunized animal, b.1-3) 36 kDa immunized animal, & c.1-3) 64 kDa immunized animal. Arrows indicating the infected cells. Magnification 10×100X (oil immersion) (Olympus Japan).

Table 2. Parasite loads in the spleen of infected and immunized animals.

| Group (n=8)          | Mean LDU (Amount of amastigotes/Number of Nucleated cells) × Weight of organ(mg)) | Mean Splenic Index |
|----------------------|----------------------------------------------------------------------------------|-------------------|
|                      |                                                                                  | Splenic Index is measured as the ratio of spleen weight to whole body weight multiplied by a hundred |
| Unimmunized-Infected | 4277.3 ±661.1 SEM                                                               | 0.322 ±0.0567 SEM |
| CFA only             | 4602.6 ±931.02 SEM                                                              | 0.368 ± 0.0534 SEM |
| Immunized with 64 kDa| 178.71 ± 47.03 SEM (p=0.0002)                                                   | 0.145 ± 0.048 SEM (p=0.0050) |
| Immunized with 36 kDa| 332.2 ± 105.32 SEM (p=0.0002)                                                   | 0.216 ± 0.067 SEM (p=0.0303) |
| Immunized with 29 kDa| 478.5 ± 50.10 SEM (p=0.0002)                                                   | 0.151 ± 0.013 SEM (p=0.0012) |
| Healthy              | NA                                                                               | 0.168 ± 0.0548 SEM |

Statistical comparison between Infected and test group. Statistics Mann-Whitney t-test. Level significance, ns P > 0.05, * P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001
Figure 2. Mean parasite load and splenic index from the spleen of different animal groups. LDU= *Leishmania donovani* unit. (Bradley & Kiskley 1977). Splenic index, the ratio of (spleen weight/whole body weight) × 100. N=8. Mean ±SEM. Statistical comparison between Infected and test group. Mann-Whitney t-test. Level of significance, ns P > 0.05, * P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.

**Splenic culture, parasite growth**

To account for any residual viable parasites in the spleen of immunized animals, we conducted the spleen tissue culture. The spleen cultures from unimmunized animals showed motile promastigotes as early as day 5 post-inoculation in concordance with a high parasitic load. (Figure 3). The promastigotes became visible in animals immunized with 36 kDa and 29 kDa proteins by day 14, indicating a significantly lower number of viable parasites in these animals as compared to unimmunized groups. However, no promastigotes could be detected in 64 kDa immunized group animal spleen cultures throughout 14-day culture, indicating no viable parasites in spleen. (Supplementary Table 5).

![Figure 3. Median promastigote growth in different groups at day zero, day 5, day 7, and day 14th.](image-url)
The immunization with multiepitope antigens induced normalization of macrophage functions for effective clearance of intracellular parasites

To further evaluate the mechanism of protection in immunized animals, we checked the functional status of peritoneal macrophages from these animals in terms of their capability to clear the intracellular parasites and produce Reactive oxygen species (ROS) as a signature of normalized oxidative burst.

Parasite clearance assay

CFSE-stained parasite clearance assay showed a significant difference in the level of infection at 12 hours, 24 hours & 48 hours post-infection in vitro compared to cells from unimmunized-infected hamsters (Figure 4A) (Supplementary Image 16A-16C & Supplementary Table 6). At 12 hours, the mean fluorescence intensity (MFI) from cells of all three immunized groups were significantly lower compared to MFI values from uninfected or unimmunized-infected animals, indicating facilitated parasite clearance by cells from immunized animals. The parasite clearance was significant at 24 hours and 48 hours also, indicating the normalized functional status of macrophages to clear the intracellular parasites after immunization.

The ability of macrophages to clear the intracellular parasites depends upon their ability to produce reactive oxygen species (ROS). The *Leishmania*-infected macrophages during active disease are shown to have a stunted ability to produce ROS due to *Leishmania*-mediated down-modulation of the oxidative burst in infected macrophages. Therefore, the restoration of macrophage functions can be determined by their capability to induce ROS upon stimulation. We assessed the functional state of macrophages from immunized animals for the production of ROS as determined by the DCFDA assay. For estimation of ROS, we estimated the level of fluorescence emitted due to 2′,7′-dichlorofluorescein (DCF) which is directly proportional to the production of ROS (Supplementary Figure 17A & 17B), interpreted in the terms of the relative level of ROS production in cells from immunized compared to unimmunized animals, termed as ‘ROS production Index (RPI)’. The difference in ROS production in cells from immunized animals was significantly higher compared to unimmunized-infected samples from 12 hours onwards for 64 kDa (2.24±1.12 SEM, p=0.0011), while this difference became statistically significant for all the three proteins at 24 hours with an RPI of 1.23±0.68 SEM p= 0.0019) for 64 kDa group; 1.11±0.32 SEM p=0.0002) for 36 kDa and 0.93 ±0.31 SEM, p= 0.0002) for 29 kDa (Figure 4B) (Supplementary Table 6). A close to 1 value of RPI was equivalent to ROS produced by naïve cells, and an indicator of the normalized functional status of macrophages from immunized groups. These findings were in perfect correlation with parasite clearance assay, where higher parasite clearance levels from macrophages of immunized animals were achieved, indicating the enhanced leishmanicidal activity due to enhanced oxidative burst against *Leishmania donovani* in immunized animals.
Immunization with multiepitope protein (64 kDa) induces a strong Th-1 polarized response in the spleen of immunized animals

To further understand the nature of protective responses generated in the spleen of immunized animals, we conducted a quantitative real-time PCR analysis for Th1 cytokines and genes related to T-cell activation. The results for real-time PCR were interpreted in terms of fold change with respect to unimmunized animals (Figure 5). Real-time PCR-based immuno-profiling revealed a strong Th1-biased immune profile of the spleen for all the three immunized groups, indicating a significant upregulation of IFN-γ (33-fold in case of 64 kDa immunized animals) compared to unimmunized controls (Figure 5A). A similar trend was observed for the 36 kDa immunized group (11.6-fold) and for 29 kDa the increase was 6.9-fold. The expression of signature Th1 cytokines like IFN-γ, IL-12, and TNF-α, was found to be significantly upregulated in immunized animals with strikingly better in the 64 kDa group (Figure 5B-5C), which is in coherence with macrophage activation and ROS production [4,60,61]. The IL-21, which is an activator of cytotoxic T-lymphocytes (CTL) and has a significant role in the clearance of intracellular infection, was also found to be significantly upregulated in 64 kDa and 36 kDa at 16 and 9.8-fold respectively (Figure 5D). The IL-21 is produced by T helper cells and affects NK cells along with CD8+ T cells. Additionally, the IL-21 has also been reported to revert CTL exhaustion and promote antigen-specific T cell activation [62–65]. Further, immune-profiling suggested a high level of inflammation and recruitment of activated T cells in the case of the 64 kDa group based on elevated levels of Chemokine (C-X-C motif) ligand 9 (CXCL9), the Chemokine receptor CXCR3 & C-C chemokine receptor type 7 (CCR7). The levels of CXCL-9 were 41 times higher in the 64 kDa immunized group and 6-fold higher in the
case of 36 kDa, although the levels for 29 kDa remained at only 3.5-fold higher yet were better compared to the infection alone group (0.8-fold change). Statistically, the data was significant only for 64 kDa protein. The IL23R, which is an indicator of the inflammatory profile, was 11-fold higher in 64 kDa immunized animals, but only 1.6-fold and 2.6-fold higher in for 36 kDa group and 29 kDa group respectively, not being statistically significant. The level of CCR7, a lymphoid homing receptor, was a 12-fold increase in the 64 kDa immunized group. 2.7-fold higher for the 29 kDa immunized group and 1.3-fold higher for the 36 kDa immunized animal group (Supplementary Figure 18). The expression levels of (T-box transcription factor) TBX21 for 64 kDa were 26-fold higher along with 2.8-fold for 36 kDa and 1.7-fold for 29 kDa, all of which were significantly higher than the unimmunized group, further indicating the development of Th1 biased immune-response with immunization (Figure: 5E). The expression level of L-selectin which is a secondary lymphoid tissue homing receptor, an indicator of memory T cell response, was significantly upregulated at 6.6, 1.6 and 2.6-fold change in 64 kDa, 36 kDa, and 29 kDa immunized animals compared to infected unimmunized animal groups, indicating T cell activation and formation of memory component (Figure: 5F). In contrast to the Th1 profile, the markers for the Th2 cytokine profile showed a low level of expression in the case of immunized animals with all three antigen constructs. Most crucially, the levels of IL-10 and TGF-β remained significantly low for all immunized groups except 29 kDa (at a 3.7-fold increase) (Figure 5G & 5H), further indicating the predominance of Th1 polarized response in immunized animals compared to the unimmunized-infected group.

Further, the levels of programmed death-ligand 1 (PD-L1: CD-274), a major immunosuppressor was significantly lower in all the immunized groups compared to unimmunized infected animals (Supplementary Figure 18).
Figure 5. Relative fold change in gene expression levels of a) IFN-γ, b) IL-12, c) TNF-α, d) IL-21, e) TBX21, f) L selectin, g) IL-10 & h) TGF-β from immunized and unimmunized animal’s spleen. n=8 for 64 kDa & 36 kDa, n=7 for 29 kDa & n= 5 for infected. Mean values ± SEM. Statistics Mann-Whitney t-test Level significance, ns p > 0.05, * p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

The multiepitope proteins induced activation of human polyfunctional T-cells ex-vivo:

To evaluate the T-cell activation potential of the vaccine proteins, we checked the ex vivo stimulation of polyfunctional T-cells in healthy human PBMCs with these proteins. Based on cytokine profile of individual T cells as calculated using Boolean Gating for INF-γ, TNF-α & IL-2, and IL-10 secretion, we found 36 kDa construct to be the highest inducer of triple-positive T cells (cells making IFN-γ, TNF-α, and IL-2 simultaneously) at 0.96% (mean ± 0.47 SD), which was higher than LPSA induced T cells at 0.55% (mean ± 0.073 SD) respectively. The 29 kDa and 64 kDa antigens were also able to induce the cells at a comparable frequency of 0.78% (mean ± 0.35 SD) & 0.49% (mean ±0.10 SD) respectively (Figure 6A). These values were higher than PMA-ionomycin induced T cells and comparable to PHA-induced T cells at 0.46 (mean ±0.11 SD) and 0.84% (mean ±0.64 SD) respectively. Besides triple-positive cells, the frequency of dual positive (INF-γ & TNF-α) T cells were also significantly higher for all the 3 proteins when compared to LPSA. The highest frequency of dual positive cells, for IFN-γ and TNF-α, was present for 64 kDa protein at an average 3.97% (mean ±0.71 SD, p=0.0286) compared to LPSA induced population of 0.53% (mean ± 0.11 SD) T cells. Similarly, a significantly higher number was observed for 36 kDa protein at average frequency of 3.39% (mean ±1.4 SD, p=0.0286) cells and 1.67% (mean ± 0.20 SD, p=0.0286) cells for 29 kDa (Figure: 6B).

The frequency of T cells producing IFN-γ alone was found to be very high post-stimulation with 36 kDa and 64 kDa at an average of 10% (mean ±1.54 SD, p=0.0286) and 8.27% (mean ± 0.8 SD, p=0.0286) of total T cells respectively, while the 29 kDa induced 5.5% cells (mean ± 0.52 SD, p=0.0286) (Figure 6C). This was further supported by high level of IFN-
γ in culture supernatant as checked by ELISA (Supplementary Image 23). This data supports our premise of selecting T cell-specific epitopes using IFNepitope tool in the case of 36 kDa and 29 kDa being strong IFN-γ inducers. Besides IFN-γ, we detected a high frequency of T cells producing TNF-α also, which is a protective cytokine and supports IFN-γ based Th1 cytokine axis through IL-12 and enhances IFN-γ production [66,67]. The 64 kDa antigen was able to induce an average 21% (mean ±2.4 SD, p=0.0079) of T cells for TNF-α production, while 36 kDa induced 18% (mean ±5.0 SD, p=0.0079) and 29 kDa induced only 7.35% (mean ±3.06 SD) of cells (Figure 6D). Further, IL-2 production was also found to be significant for 36 kDa at mean frequency of 9.2% (mean ±1.4 SD, p=0.0286) T cells, which was 4.3% for 64 kDa (mean ± 0.37 SD, p=0.0286) and 3.9% for 29 kDa (mean ± 0.93 SD) (Figure 6E). It was interesting to note that the frequency of IL-10 producing T-cells in the same experiment was very low at only 0.9% (±0.33 SD) for 64 kDa and 1.39% (±0.57 SD) for 36 kDa, which was comparable to the number of cells induced by LPSA [1.2%(±0.29SD)] (Figure 6F). The low levels of IL-10 correlated with higher levels of protection as in case of both 64 kDa and 36 kDa minimal IL-10 presence was detected in both human PBMC stimulation experiment as well as in spleens of both 64 kDa and 36 kDa immunized animals.
Discussion

The previous generation of vaccines for visceral leishmaniasis has mainly relied on the generation of enhanced IFN-γ response, with few attempts at a possible suppression of IL-10 [30]. So far, the vaccine designs have been based on either whole attenuated parasite form or multiple antigens and due to partial efficacy, none is yet licensed for human use [68]. These whole antigen-based vaccines could carry a mix of high affinity and low-affinity random epitopes. In this regard, the selection of strong binders for vaccine designing has been shown to induce inflammatory responses and the generation of memory T cells [69–74]. An epitope has a quantitative and qualitative role in immune-response
generation, specifically T-cell receptor (TCR) dependent memory cell formation [14]. The role of a single epitope in TCR activation and its downstream effect is a matter of debate and research [9], because the substitution of a single amino acid in epitope sequence can alter the immune response to a great extent [75,76]. The prevailing qualitative model of memory formation depends on the cytokine environment generated by APC and other supportive cells [14,77]. The quantitative model however relies on TCR and immune-signalosome complex involving peptide-MHC-TCR interaction strength, amount of antigen, and costimulatory molecule interaction [28,78–80]. In vaccine designing the level of control on the quantitative model is debatable and cannot be controlled directly. In the context of the qualitative model, the modern immunoinformatic approach can be utilized to dictate the choice of the epitope, which can affect the TCR-peptide-MHC signalsosome response by utilization of either high or low-affinity epitopes [81,82]. The approach of MHC-I and MHC-II specific epitope identification has been utilized by researchers in the last 5 years for Leishmaniasis vaccine research [83]. However, most of these vaccine ideas are limited to in-silico docking models. Additionally, the number of epitopes included in a majority of research has remained limited to selective few epitopes, limiting the overall size of vaccine candidates [83–86]. Since larger size antigen is known to generate a higher degree of immunogenicity, this is a limitation in the case of designed vaccines because the smaller size antigens are generally poor immunogens [87]. On the other hand, the variants with a large number of epitopes as in chimeric molecules have shown promising results [88].

Previous studies from our lab have identified three antigenic genes of *Leishmania donovani* from an indigenously made cDNA library [45]. When repeatedly tested as potential vaccines in hamster and mice model, the responses indicated strong IFN-γ induction and an optimal level (70-80%) of protection. Although a significant reduction in splenic parasite burden was observed, yet sterile immunity could not be achieved, probably due co-induction of IL-10 in the immunized animals [46,47,89]. Our current work is a refinement of the previous work and takes one step further from whole antigen-based subunit vaccine to T cell epitope-based vaccine. In the present proof-of-concept study, we have tried the possibility of developing T cell epitope-based vaccine candidates based on multiple MHC-I and MHC-II epitopes, along with candidates exclusively based on multiple INF-γ specific T cell epitopes, from the three previously identified cDNA clones of *Leishmania donovani* [45]. Based on the immunoinformatic mapping, the data gave a large number of MHC-I and MHC-II binding epitopes with the majority of epitopes being overlapping and present in a cluster of epitope-rich islands. Similar results were obtained with usage of IFNepitope tool. The presence of T-cell epitopes in clusters could be of some evolutionary significance or just a chance occurrence with our 3 antigen genes, which needs to be studied and resolved further. We couldn’t come up with any previous study in literature to account for the clustering of T cell epitopes. In our opinion, the clustering of immunodominant epitopes could occur due to evolutionary selective pressure in which certain regions of antigens escape the MHC affinity due to reasons not known yet. One study does point towards common amino acid polymorphisms and epitope binding repertoires in HLA-DRB1 associated with lower Leishmaniasis susceptibility [90]. Our study further raises the question regarding epitope representation on MHC molecule, since the epitope identification done on human MHC-binding based selection, showed their ability to raise a T cell-based immunity in hamster model also, points towards the conserved nature of high-affinity epitopes across species. The hypothesis of specific epitopes, both conformational and linear, being conserved through evolution and shared in antigens from different species, have been validated by different publications [91–94].

The three designed multi-epitope constructs in this study, when used as vaccine in a hamster model of experimental visceral Leishmaniasis along with FCA, induced a significant protective response to a virulent challenge along with a strong Th-1 biased immune response. Our observations for the designed vaccine candidates, especially 64 kDa and 36 kDa, indicated a significant improvement over the parent antigens identified earlier and used as base genes for selection of epitopes in this study, as evident from a significant
increase in the protection level with even achieving a sterile immunity with 64 kDa protein and a notable reduction of IL-10 cytokine production also correlating with increased vaccine efficacy [46,47]. Scanty parasites seen in splenic touch imprints of 64 kDa immunized animals could be most likely be remnants of dead parasites, as no motile promastigotes could be observed in the splenic culture assay with these spleen tissues. Splenic culture assay is considered a gold-standard method of detecting the viable parasites in the spleen as only living and viable parasites would be able to differentiate to promastigote form [95,96]. Active Leishmania infection would normally lead to hepatosplenomegaly with an increase in spleen size and weight, which could be observed in the infected but unimmunized animals. However, the parasite load as well as the splenic index, which is a proxy indicator of spleen weight, was consistently low in animals immunized with all the three multiepitope proteins designed in the current study, which primarily indicated the protective efficacy of these vaccine candidates in terms of restricting the parasite growth.

The Leishmania parasite completely hijacks the killing machinery of host cells, i.e., macrophages. A predominance of immuno-suppressive macrophages with a subdued capacity to generate optimum oxidative burst, which is necessary for clearance of parasites, is seen in active Leishmania disease [97]. Thus, the protective response of any vaccine would envisage the reversal of this process and conversion of immuno-suppressive to activated macrophages having enhanced capacity to generate enough reactive oxygen species to clear the intracellular parasites. The peritoneal macrophages from the immunized animals displayed the characteristics of normalized functions with enhanced capability to clear the intracellular parasites very effectively along with the generation of significantly higher amounts of ROS, indicating the restoration of the killing mechanisms and generation of oxidative burst (87-89). Hyper responsive adaptation in macrophages is an increased expression of inflammatory genes after re-stimulation of macrophages. This depends upon increased expression of signaling molecules, metabolic reprogramming, and the epigenetic change at cis-regulatory elements. Perseverance of these features even after elimination of stimulus can facilitate or potentiate secondary activation [98,99]. Our results can be inferred as hyperresponsive adaptation arising due to immunization by the multiepitope proteins, when used as a vaccine, in the experimental model [99–101]. Although, the details of the exact mechanism for this state in our study remains to be explored, yet the functioning of the iNOS pathway in immunized animals seems evident for their ability to clear in-vitro reinfection, as the ROS pathway, in turn, is connected to inflammasome activity in macrophage [102,103]. This is in coherence with previous studies where KOS generation has been shown in support of Leishmania donovani clearance [104,105]. The protective response in our study is supported by a high level of inflammation and T cell activation in hamsters immunized with the designed multiepitope proteins. The data indicates an upregulated expression of IFNγ, IL-12, and TNF-α, which forms the signature for Th1 type of immune-response being induced in the immunized animals, leading to a protective response as seen in these animals. This type of response was most evident in animals immunized with 64 kDa protein, which induced a sterile immunity. Development of memory T cell responses was supported by elevated expression of genes like TBX21, IL-21, IL-23r, IL-12, and L-Selectin in the spleen tissue of all the immunized animals, especially with 64 kDa protein (Supplementary Figure 18). Among these, the IL-21 has been shown to mediate inflammatory axis in parasite-infected organs, mice deficient in IL-21 are shown to be unable to clear parasite in a TBX21, STAT-4 and IL-12 dependent manner [106,107]. IL23r is present on T cells and NK cells & has been shown to have a protective role in VL infection via IL-17 mediated pathways [108]. Further T cell functioning and development of proliferative T cells was evident from high levels of CXCL9, CXCR3 in the case of 64 kDa immunized group, further indicative of Th1 polarization (Supplementary Figure 18). The CXCL9 increases transcription of T-bet and RORγ, leading to the polarization of Foxp3 type I regulatory (Tr1) cells or Thelper 17 (Th17) cells from naive T cells via STAT1, STAT4, and STAT5 phosphorylation [109]. The Treg component was low in immunized animals in our study as indicated by significantly down-regulated expression of IL-10 and TGF-β. This type of response is important for any
A vaccine to be efficacious against this parasite, since the pathogenesis of *Leishmania* infection is marked by presence of Treg cells, which cause a broad level of immune suppression (92,93).

A further elaboration of protective responses in the human context was shown by the activation of polyfunctional T cells. Polyfunctional T cells have been correlated with protection in multiple studies [110,111]. It was interesting to find that the designed protein constructs were able to induce the polyfunctional T-cells in the PBMC of a healthy human donor to produce IFN-γ, TNF-α, and IL-2 simultaneously. Similarly, cytokine levels and frequency of IFN-γ producing T cells were significantly high for all the proteins asserting the role of dominant and IFN-γ specific epitopes as the inducer of Th1 responses, justifying our epitope-selection process. The induction values were equivalent and higher in some cases when compared to other candidates tested in other studies [112–114]. This data further emphasizes the protective potential of our antigen constructs via the induction of polyfunctional T cells.

In summary, among the three designed multi-epitope constructs, the 64 kDa candidate contained the largest number of dominant epitopes, which were both strong binders of MHC-I and MHC-II along with regions of IFN-γ specific epitopes and this protein induced a sterile immunity in hamsters when used as a vaccine. The protective nature of 64 kDa was also evident by the generation of polyfunctional T cells and very high frequency of IFN-γ and TNF-α producing dual-positive T-cells on activation of human PBMC with this protein. High-affinity dominant epitopes are generally considered immune-responsive with the potential to activate cytotoxic T lymphocytes (CTLs), and a skewness towards the Th1 cytokine profile [25,26]. The 36 kDa protein, designed with IFN-γ specific epitopes with a preference for epitopes that had an affinity towards MHC-I, but also contained some dual-specificity epitopes for both MHC-I and MHC-II, was also able to reduce parasite burden significantly with inflammatory response and absence of any immune-suppressive responses, while the sterile immunity could not be achieved with this protein. The results from human PBMC stimulation indicated polyfunctional T cell activation along with IFN-γ and TNF-α production capability. The levels of IFN-γ in suboptimal concentrations have been shown to have a vital role in the optimization of innate immune cell functions including phagocytosis and destruction of reminiscent pathogens [115]. Previously, other researchers have also shown a limited role of CTL responses in the clearance of parasites [116]. The 29 kDa protein was designed from IFN-γ inducing epitopes with affinity to MHC-II, it also contained some dual-specificity epitopes for both MHC-I and MHC-II. Immunization with 29 kDa induced a lower level of protection, although showed increased IFN-γ production, yet had very insignificant effect on IL-10 producing T cells. However, 29 kDa contained only 24 core epitopes, compared to 63 epitopes in 36 kDa and 1317 epitopes in 64 kDa in various overlapping configurations, which seem to have limited its protective efficacy.

**Conclusion**

Visceral Leishmaniasis has remained without a protective vaccine probably because of the lack of a candidate that could generate a predominant Th1 polarized response while keeping the immuno-suppressive responses to a minimum. We have shown the possibility to develop a vaccine candidate, the 64 kDa protein, with tailored Th1 responses by the selection of T cell-specific high-affinity and IFN-γ inducing epitopes, which could induce a sterile immunity against a lethal challenge. Our other two proposed candidates were also able to induce a significant level of protection in the hamster model but with limited efficacy. The exact mechanism of these responses along with the kinetics of T cell epitopes remains to be further evaluated. This approach opens the possibility of developing tailored immune response-specific vaccines against other infectious agents also such as HIV, malaria, coronavirus or even cancer.
Acknowledgments: The authors would like to acknowledge the Indian Council of Medical Research (ICMR), New Delhi for the research fellowship (Ref. No. 3/1/3JRF-2014/HRD-81(30327)) provided to AA.

Conflicts of Interest: Authors declare no conflict of interest.

References:

[1] Zutshi S, Kumar S, Chauhan P, Bansode Y, Nair A, Roy S, et al. Anti-Leishmanial Vaccines: Assumptions, Approaches, and Annulments. Vaccines 2019;7. https://doi.org/10.3390/vaccines7040156.

[2] WHO | Weekly Epidemiological Record, 22 September 2017, vol. 92, 38 (pp. 557–572). WHO n.d. http://www.who.int/wer/2017/wer9238/en/ (accessed November 19, 2020).

[3] Bi K, Chen Y, Zhao S, Kuang Y, John Wu C-H. Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study. BioMed Res Int 2018;2018:9872095. https://doi.org/10.1155/2018/9872095.

[4] Dayakar A, Chandrasekaran S, Kuchipudi SV, Kalangi SK. Cytokines: Key Determinants of Resistance or Disease Progression in Visceral Leishmaniasis: Opportunities for Novel Diagnostics and Immunotherapy. Front Immunol 2019;10:670. https://doi.org/10.3389/fimmu.2019.00670.

[5] Medina-Centro AA, Osorio EY, Saldarriaga OA, Travi BL, Kong F, Spratt H, et al. Splenic CD4+ T Cells in Progressive Visceral Leishmaniasis Show a Mixed Effector-Regulatory Phenotype and Impair Macrophage Effector Function through Inhibitory Receptor Expression. PLOS ONE 2017;12:e0169496. https://doi.org/10.1371/journal.pone.0169496.

[6] Rodrigues V, Cordeiro-da-Silva A, Laforge M, Silvestre R, Estaquier J. Regulation of immunity during visceral Leishmania infection. Parasit Vectors 2016;9:118. https://doi.org/10.1186/s13071-016-1412-x.

[7] Srivastava S, Shankar P, Mishra J, Singh S. Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasit Vectors 2016;9:277. https://doi.org/10.1186/s13071-016-1553-y.

[8] Hwang J-R, Byeon Y, Kim D, Park S-G. Recent insights of T cell receptor-mediated signaling pathways for T cell activation and development. Exp Mol Med 2020;52:750–61. https://doi.org/10.1038/s12276-020-0435-8.

[9] Buckle AM, Borg NA. Integrating Experiment and Theory to Understand TCR-pMHC Dynamics. Front Immunol 2018;9:2898. https://doi.org/10.3389/fimmu.2018.02898.

[10] Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227–42. https://doi.org/10.1038/nri3405.

[11] Zoete V, Irving M, Ferber M, Coundet MA, Michielin O. Structure-Based, Rational Design of T Cell Receptors. Front Immunol 2013;4:268. https://doi.org/10.3389/fimmu.2013.00268.

[12] Carpenter SM, Nunes-Alves C, Booty MG, Way SS, Behar SM. A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness Cost That Is Modified by TCR Affinity during Tuberculosis. PLOS Pathog 2016;12:e1005380. https://doi.org/10.1371/journal.ppat.1005380.

[13] Coombs D, Goldstein B. T cell activation: Kinetic proofreading, serial engagement and cell adhesion. J Comput Appl Math 2005;184:121–39. https://doi.org/10.1016/j.cam.2004.07.035.

[14] Courtenay AH, Lo W-L, Weiss A. TCR Signaling: Mechanisms of Initiation and Propagation. Trends Biochem Sci 2018;43:108–23. https://doi.org/10.1016/j.tibs.2017.11.008.

[15] Antunes R, Sidney J, Lindestam Arlehamn CS, Grifoni A, Dhanda SK, et al. A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models for Mycobacterium tuberculosis and Bordetella pertussis. Front Immunol 2018;9. https://doi.org/10.3389/fimmu.2018.02778.

[16] Buckle AM, Borg NA. Integrating Experiment and Theory to Understand TCR-pMHC Dynamics. Front Immunol 2018;9:2898. https://doi.org/10.3389/fimmu.2018.02898.

[17] Bi K, Chen Y, Zhao S, Kuang Y, John Wu C-H. Current Visceral Leishmaniasis Research: A Research Review to Inspire Future Study. BioMed Res Int 2018;2018:9872095. https://doi.org/10.1155/2018/9872095.

[18] Tian Y, da Silva Antunes R, Sidney J, Lindestam Arlehamn CS, Grifoni A, Dhanda SK, et al. A Review on T Cell Epitopes Identified Using Prediction and Cell-Mediated Immune Models for Mycobacterium tuberculosis and Bordetella pertussis. Front Immunol 2018;9. https://doi.org/10.3389/fimmu.2018.02778.

[19] Pentier J, Sewell A, Miles JJ. Advances in T-Cell Epitope Engineering. Front Immunol 2013;4. https://doi.org/10.3389/fimmu.2013.00133.
[20] Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, et al. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay. J Virol 2000;74:8541–9. https://doi.org/10.1128/jvi.74.18.8541-8549.2000.

[21] Nelson D, Bundell C, Robinson B. In Vivo Cross-Presentation of a Soluble Protein Antigen: Kinetics, Distribution, and Generation of Effector CTL Recognizing Dominant and Subdominant Epitopes. J Immunol 2000;165:6123–32. https://doi.org/10.4049/jimmunol.165.11.6123.

[22] Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol Baltim Md 1995 1997;159:5956–602.

[23] Daniels MA, Teixeiro E. TCR Signaling in T Cell Memory. Front Immunol 2015;6:617. https://doi.org/10.3389/fimmu.2015.00617.

[24] Olasz K, Boldizsar F, Kis-Toth K, Tarjanyi O, Hegyi A, van Eden W, et al. T cell receptor (TCR) signal strength controls arthritis severity in proteoglycan-specific TCR transgenic mice. Clin Exp Immunol 2012;167:346–55. https://doi.org/10.1111/j.1365-2249.2011.04506.x.

[25] Ahlers JD, Belyakov IM, Thomas EK, Berzofsky JA. High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. J Clin Invest 2001;108:1677–85. https://doi.org/10.1172/JCI13463.

[26] Singh R, Gupta P, Sharma PK, Ades EW, Hollingshead SK, Singh S, et al. Prediction and characterization of helper T-cell epitopes from pneumococcal surface adhesin A. Immunology 2014;141:514–30. https://doi.org/10.1111/imm.12194.

[27] Tao X, Constant S, Jorritsma P, Bottomly K. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J Immunol Baltim Md 1995 1997;159:5956–63.

[28] Bhattacharyya ND, Feng CG. Regulation of T Helper Cell Fate by TCR Signal Strength. Front Immunol 2020;11:624. https://doi.org/10.3389/fimmu.2020.00624.

[29] van Panhuys N. TCR Signal Strength Alters T-DC Activation and Interaction Times and Directs the Outcome of Differentiation. Front Immunol 2016;7:6. https://doi.org/10.3389/fimmu.2016.00006.

[30] Joshi S, Rawat K, Yadav NK, Kumar V, Siddiqi MI, Dube A. Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches. Front Immunol 2014;5:380. https://doi.org/10.3389/fimmu.2014.00380.

[31] Arya A, Arora SK, Arya A, Arora SK. Epitope Based Vaccine Designing- A mini review. J Vaccines Immunol 2020;6:038–41. https://doi.org/10.4172/jvimi.1000036.

[32] Zhang J, He J, Liao X, Xiao Y, Liang C, Zhou Q, et al. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis. Immunobiology 2021;226:152085. https://doi.org/10.1016/j.imbiom.2021.152085.

[33] Agallou M, Margaroni M, Kotsakis SD, Karagouni E. A Canine-Directed Chimeric Multi-Epitope Vaccine Induced Protective Immune Responses in BALB/c Mice Infected with Leishmania infantum. Vaccines 2020;8. https://doi.org/10.3390/vaccines8030350.

[34] Baburaj G, Roudbari Z, Ghanbariasad A, Abdollahi A, Mohammadi E, Mortazavidehkordi N, et al. Exploring membrane proteins of Leishmania major to design a new multi-epitope vaccine using immunoinformatics approach. Eur J Pharm Sci 2020;152:105423. https://doi.org/10.1016/j.ejps.2020.105423.

[35] Atapour A, Ghalamfarsa F, Naderi S, Hatam G. Designing of a Novel Fusion Protein Vaccine Candidate Against Human Visceral Leishmaniasis (VL) Using Immunoinformatics and Structural Approaches. Int J Pept Res Ther 2021;1–14. https://doi.org/10.1007/s10989-021-10218-8.

[36] Majidiani H, Dalimi A, Ghaffarifar F, Pirestani M. Multi-epitope vaccine expressed in Leishmania tarentolae confers protective immunity to Toxoplasma gondii in BALB/c mice. Microb Pathog 2021;155:104925. https://doi.org/10.1016/j.micpath.2021.104925.

[37] Yadav S, Prakash J, Singh OP, Gedda MR, Chauhan SB, Sundar S, et al. IFN-γ+ CD4+ T cell-driven prophylactic potential of recombinant LDBPK_252400 hypothetical protein of Leishmania donovani against visceral leishmaniasis. Cell Immunol 2021;361:104272. https://doi.org/10.1016/j.cellimm.2020.104272.

[38] Ostolin TLVP, Gusmão MR, Mathias FAS, Cardoso JM de O, Roatt BM, Aguiar-Soares RD de O, et al. A chimeric vaccine combined with adjuvant system induces immunogenicity and protection against visceral leishmaniasis in BALB/c mice. Vaccine 2021;39:2755–63. https://doi.org/10.1016/j.vaccine.2021.04.004.
[39] Shermeh AS, Zahedifard F, Habibzadeh S, Taheri T, Rafati S, Seyed N. Evaluation of protection induced by in vitro matured BMDCs presenting CD8+ T cell stimulating peptides after a heterologous vaccination regimen in BALB/c model against Leishmania major. Exp Parasitol 2021;223:108082. https://doi.org/10.1016/j.exppara.2021.108082.

[40] Foroutan M, Ghaflariifar F, Sharifi Z, Dalimi A. Vaccination with a novel multi-epitope ROP8 DNA vaccine against acute Toxoplasma gondii infection induces strong B and T cell responses in mice. Comp Immunol Microbiol Infect Dis 2020;69:101413. https://doi.org/10.1016/j.cimid.2020.101413.

[41] Lu C, Meng S, Jin Y, Zhang W, Li Z, Wang F, et al. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy. Br J Haematol 2017;178:413–26. https://doi.org/10.1111/bjh.14686.

[42] Adhikari UK, Rahman MM. Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach. Infect Genet Evol 2017;56:75–91. https://doi.org/10.1016/j.meegid.2017.10.022.

[43] Saadi M, Karkhah A, Nouri HR. Development of a multi-epitope peptide vaccine inducing robust T cell responses against brucellosis using immunoinformatics based approaches. Infect Genet Evol 2017;51:227–34. https://doi.org/10.1016/j.meegid.2017.04.009.

[44] Kumar Pandey R, Ojha R, Mishra A, Kumar Prajapati V. Designing B- and T-cell multi-epitope based subunit vaccine using immunoinformatics approach to control Zika virus infection. J Cell Biochem 2018;119:7631–42. https://doi.org/10.1002/jcb.27110.

[45] Arora SK, Pal NS, Mujtaba S. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines. Exp Parasitol 2005;109:163–70. https://doi.org/10.1016/j.exppara.2004.12.009.

[46] Bhardwaj S, Vasishta RK, Arora SK. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis. Exp Parasitol 2009;121:29–37. https://doi.org/10.1016/j.exppara.2008.09.019.

[47] Masih S, Arora SK, Vasisht RK. Efficacy of Leishmania donovani ribosomal P1 gene as DNA vaccine in experimental visceral leishmaniasis. Exp Parasitol 2011;129:55–64. https://doi.org/10.1016/j.exppara.2011.05.014.

[48] Dhandha SK, Vir P, Raghava GPS. Designing of interferon-gamma inducing MHC class-II binders. Biol Direct 2013;8:30. https://doi.org/10.1186/1745-6150-8-30.

[49] Saini S, Rai AK. Hamster, a close model for visceral leishmaniasis: Opportunities and challenges. Parasite Immunol 2020;42:e12768. https://doi.org/10.1111/pim.12768.

[50] Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinforma Oxf Engl 2016;32:511–7. https://doi.org/10.1093/bioinformatics/btv639.

[51] Nielsen M, Lundegaard C, Worm P, Lauemøller SL, Lamberth K, Buus S, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci Publ Protein Soc 2003;12:1007–17. https://doi.org/10.1002/jcb.27110.

[52] Reynisson B, Barra C, Kaabinejad S, Hildebrand WH, Peters B, Nielsen M. Improved Prediction of MHC II Antigen Presentation through Integration and Motif Deconvolution of Mass Spectrometry MHC Eluted Ligand Data. J Proteome Res 2020;19:2304–15. https://doi.org/10.1021/acs.jproteome.9b00874.

[53] Singh H, Raghava GP. ProPred: prediction of HLA-DR binding sites. Bioinforma Oxf Engl 2001;17:1236–7. https://doi.org/10.1093/bioinformatics/17.12.1236.

[54] Singh H, Raghava GPS. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinforma Oxf Engl 2003;19:1009–14.

[55] Nielsen M, Lundegaard C, Lund O, Keşmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005;57:33–41. https://doi.org/10.1007/s00251-005-0781-7.

[56] Keşmir C, Nussbaum AK, Schild H, Detours V, Brunak S. Prediction of proteasome cleavage motifs by neural networks. Protein Eng 2002;15:287–96. https://doi.org/10.1093/protein/15.4.287.

[57] Mutiso JM, Macharia JC, Gichuru MM. A review of adjuvants for Leishmania vaccine candidates. J Biomed Res 2010;24:16–25. https://doi.org/10.1016/S1674-8301(10)60004-8.

[58] Shibaki A, Katz SI. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund’s adjuvant. Exp Dermatol 2002;11:126–34. https://doi.org/10.1034/j.1600-0625.2002.110204.x.

[59] Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002;2:251–62. https://doi.org/10.1038/nri778.
[60] Huang Y, Lei Y, Zhang H, Zhang M, Dayton A. Interleukin-12 treatment down-regulates STAT4 and induces apoptosis with increasing ROS production in human natural killer cells. J Leukoc Biol 2011;90:87–97. https://doi.org/10.1189/jlb.1210674.

[61] Raja MRC, Srinivasan S, Subramaniam S, Rajendran N, Sivasubramanian A, Mahapatra SK. Acetyl shikonin induces IL-12, nitric oxide and ROS to kill intracellular parasite Leishmania donovani in infected hosts. RSC Adv 2016;6:61777–83. https://doi.org/10.1039/C6RA11510A.

[62] Xu A, Zhang X, Chibbar R, Freywald A, Tikoo S, Zheng C, et al. Transgene IL-21-Engineered T Cell-Based Vaccine Potently Converts CTL Exhaustion via the Activation of the mTORC1 Pathway in Chronic Infection. World J Vaccines 2018;9:1–21. https://doi.org/10.4236/wjv.2019.91001.

[63] Parmigiani A, Pallin MF, Schmidtmaierova H, Lichtenheld MG, Pahwa S. Interleukin-21 and cellular activation concurrently induce potent cytokine function and promote antiviral activity in human CD8 T cells. Hum Immunol 2011;72:115–23. https://doi.org/10.1016/j.humimm.2010.10.015.

[64] Leonard WJ, Wan C-K. IL-21 Signaling in Immunology. F1000Research 2016;5. https://doi.org/10.12688/f1000research.7634.1.

[65] Kasaian MT, Whittles MJ, Carter LL, Lowe LD, Jussif JM, Deng B, et al. IL-21 Limits NK Cell Responses and Promotes Antigen-Specific T Cell Activation: A Mediator of the Transition from Innate to Adaptive Immunity. Immunity 2002;16:559–69. https://doi.org/10.1016/S1074-7613(02)00295-9.

[66] Shibuya K, Robinson D, Zonin F, Hartley SB, Macatonia SE, Somoza C, et al. IL-1α and TNF-α Are Required for IL-12-Induced Development of Th1 Cells Producing High Levels of IFN-γ in BALB/c But Not C57BL/6 Mice. J Immunol 1998;160:1708–16.

[67] Hernandez-Pando R, Rook GA. The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance. Immunology 1994;82:591–5.

[68] De Brito RCF, Cardoso JMD, Reis LES, Vieira JF, Mathias FAS, Roatt BM, et al. Peptide Vaccines for Leishmaniasis. Front Immunol 2018;9:1043. https://doi.org/10.3389/fimmu.2018.01043.

[69] Xiong X, Qi Y, Jiao J, Gong W, Duan C, Wen B. Exploratory study on Th1 epitope-induced protective immunity against Coxiella burnetii infection. PLoS One 2014;9:e87206. https://doi.org/10.1371/journal.pone.0087206.

[70] Chaturvedi P, Yu Q, Southwood S, Sette A, Singh B. Peptide analogs with different affinities for MHC alter the cytokine profile of T helper cells. Int Immunol 1996;8:745–55. https://doi.org/10.1093/immunol/8.5.745.

[71] Boyton RJ, Altmann DM. Is selection for TCR affinity a factor in cytokine polarization? Trends Immunol 2002;23:526–9. https://doi.org/10.1016/S1471-4906(02)02319-0.

[72] Lo-Man R, Langeveld JPM, Dériaud E, Jehanno M, Rojas M, Clément J-M, et al. Extending the CD4+ T-Cell Epitope Specificity of the Th1 Immune Response to an Antigen Using aSalmonella enterica Serovar Typhimurium Delivery Vehicle. Infect Immun 2000;68:3079–89. https://doi.org/10.1128/IAI.68.6.3079-3089.2000.

[73] Moro-García MA, Mayo JC, Sainz RM, Alonso-Arias R. Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes. Front Immunol 2018;9:339. https://doi.org/10.3389/fimmu.2018.00339.

[74] Butler NS, Harty JT. The role of inflammation in the generation and maintenance of memory T cells. Adv Exp Med Biol 2010;684:42–56. https://doi.org/10.1007/978-1-4419-6451-9_4.

[75] Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo. J Exp Med 1995;181:1569–74.

[76] Tamura T, Ariga H, Kinashi T, Uehara S, Kikuchi T, Nakada M, et al. The role of antigenic peptide in CD4+ T helper phenotype development in a T cell receptor transgenic model. Int Immunol 2004;16:1691–9. https://doi.org/10.1093/intimm/dxh170.

[77] Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev Immunol 2003;3:939–51. https://doi.org/10.1038/nri1248.

[78] Smith-Garvin JE, Koretzky GA, Jordan MS. T Cell Activation. Annu Rev Immunol 2009;27:591–619. https://doi.org/10.1146/annurev.immunol.021908.132706.

[79] Coombs D, Dushek O, van der Merwe PA. A Review of Mathematical Models for T Cell Receptor Triggering and Antigen Discrimination. In: Molina-París C, Lythe G, editors. Math. Models Immune Cell Biol., New York, NY: Springer; 2011, p. 25–45. https://doi.org/10.1007/978-1-4419-7725-0_2.

[80] Zhu Y, Yao S, Chen L. Cell surface signaling molecules in the control of immune responses: a tide model. Immunity 2011;34:466–78. https://doi.org/10.1016/j.immuni.2011.04.008.
[81] Adhikari UK, Tayebi M, Rahman MM. Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus. J Immunol Res 2018;2018:6718083. https://doi.org/10.1155/2018/6718083.

[82] Kar T, Narsaria U, Basak S, Deb D, Castiglione F, Mueller DM, et al. A candidate multi-epitope vaccine against SARS-CoV-2. Sci Rep 2020;10:10895. https://doi.org/10.1038/s41598-020-67749-1.

[83] Bordbar A, Bagheri KP, Ebrahimi S, Parvizi P. Bioinformatic analyses of immunogenic T-cell epitopes of LeIF and PpSP15 proteins from Leishmania major and sand fly saliva used as model antigens for the design of a multi-epitope vaccine to control leishmaniasis. Infect Genet Evol 2020;80:104189. https://doi.org/10.1016/j.meegid.2020.104189.

[84] Dikhit MR, Kumar A, Das S, Dehury B, Rout AK, Jamal F, et al. Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis. Front Immunol 2017;8:1763. https://doi.org/10.3389/fimmu.2017.01763.

[85] Vakili B, Nezafat N, Zare B, Erfani N, Akbari M, Ghasemi Y, et al. A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice. Med Microbiol Immunol (Berl) 2020;209:69–79. https://doi.org/10.1007/https://doi.org/10.1007/s00430-019-00640-7.

[86] Khatoon N, Pandey RK, Prajapati VK. Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. Sci Rep 2017;7:8285. https://doi.org/10.1038/s41598-017-08842-w.

[87] Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology E-Book. Elsevier Health Sciences; 2017.

[88] Zhang J, He J, Li J, Zhou Q, Chen H, Zheng Z, et al. The immunogenicity and protective immunity of multi-epitope DNA prime-boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis. PLOS ONE 2020;15:e0230381. https://doi.org/10.1371/https://doi.org/10.1371/journal.pone.0230381.

[89] Ratna T, Arora SK. Leishmania recombinant antigen modulates macrophage effector function facilitating early clearance of intracellular parasites. Trans R Soc Trop Med Hyg 2016;110:610–9. https://doi.org/10.1093/trstmh/trw068.

[90] de Vrij N, Meysman P, Gielis S, Adriaensen W, Laukens K, Cuypers B. HLA-DRB1 Alleles Associated with Lower Leishmaniasis Susceptibility Share Common Amino Acid Polymorphisms and Epitope Binding Repertoires. Vaccines 2021;9. https://doi.org/10.3390/vaccines9030270.

[91] Mitran CJ, Yanow SK. The Case for Exploiting Cross-Species Epitopes in Malaria Vaccine Design. Front Immunol 2020;11:335. https://doi.org/10.3389/fimmu.2020.00335.

[92] Bolander ME, Robey PG, Fisher LW, Conn KM, Prabhadkar BS, Termine JD. Monoclonal antibodies against osteonectin show conservation of epitopes across species. Calcif Tissue Int 1989;45:74–80. https://doi.org/10.1007/BF02561405.

[93] Westernberg L, Schulten V, Greenbaum JA, Natali S, Trippe V, McKinney DM, et al. T-cell epitope conservation across allergen species is a major determinant of immunogenicity. J Allergy Clin Immunol 2016;138:571-578.e7. https://doi.org/10.1016/j.jaci.2015.11.034.

[94] Piel LMW, Durée CJ, White SN. Proteome-wide analysis of Coxiella burnetii for conserved T-cell epitopes with presentation across multiple host species. BMC Bioinformatics 2021;22:296. https://doi.org/10.1186/s12859-021-04181-w.

[95] Thakur S, Joshi J, Kaur S. Leishmaniasis diagnosis: an update on the use of parasitological, immunological and molecular methods. J Parasit Dis 2020;44:253–72. https://doi.org/10.1007/s12639-020-01212-w.

[96] Sundar S, Rai M. Laboratory Diagnosis of Visceral Leishmaniasis. Clin Diagn Lab Immunol 2002;9:951–8. https://doi.org/10.1128/CDLI.9.5.951-958.2002.

[97] Tomiott-Pellissier F, Bortoleti BT da S, Assolini JP, Gonçalves MD, Carloto ACM, Miranda-Sapla MM, et al. Macrophage Polarization in Leishmaniasis: Broadening Horizons. Front Immunol 2018;9:2529. https://doi.org/10.3389/fimmu.2018.02529.

[98] Chen F, Wu W, Millman A, Craft JF, Chen E, Patel N, et al. Neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion. Nat Immunol 2014;15:938–46. https://doi.org/10.1038/ni.2984.

[99] Natoli G, Ostuni R. Adaptation and memory in immune responses. Nat Immunol 2019;20:783–92. https://doi.org/10.1038/s41590-019-0399-9.

[100] Tercan H, Riksen NP, Joosten LAB, Netea MG, Bekkering S. Trained Immunity: Long-Term Adaptation in Innate Immune Responses. Arterioscler Thromb Vasc Biol 2021;41:55–61. https://doi.org/10.1161/ATVBAHA.120.314212.

[101] Mortha A, Burrows K. Cytokine Networks between Innate Lymphoid Cells and Myeloid Cells. Front Immunol 2018;9:191. https://doi.org/10.3389/fimmu.2018.00191.
Zamboni DS, Sacks DL. Inflammasomes and Leishmania: in good times or bad, in sickness or in health. Curr Opin Microbiol 2019;52:70–6. https://doi.org/10.1016/j.mib.2019.05.005.

Ribeiro HAL de, Maioli TU, Freitas LM de, Tieri P, Castiglione F. A mathematical model of murine macrophage infected with Leishmania sp. 2018 IEEE Int. Conf. Bioinforma. Biomed. BIBM, 2018, p. 1425–30. https://doi.org/10.1109/BIBM.2018.8621351.

Basu Ball W, Mukherjee M, Das PK. Leishmania donovani activates uncoupling protein 2 transcription to suppress mitochondrial oxidative burst through differential modulation of SREBP2, Sp1 and USF1 transcription factors. Int J Biochem Cell Biol 2014;48:66–76. https://doi.org/10.1016/j.biocel.2014.01.004.

Kyriazis ID, Koutroni OS, Aligiannis N, Karampetsou K, Skaltsounis A-L, Dotsika E. The leishmanicidal activity of oleuropein is selectively regulated through inflammation- and oxidative stress-related genes. Parasit Vectors 2016;9:441. https://doi.org/10.1186/s13071-016-1701-4.

Singer B, Chauhan SB, Kumar R, Singh SS, Ng S, Amante F, et al. A molecular signature for CD8+ T cells from visceral leishmaniasis patients. Parasite Immunol 2019;41:e12669. https://doi.org/10.1111/pim.12669.

Solaymani-Mohammadi S, Eckmann L, Singer SM. Interleukin (IL)-21 in Inflammation and Immunity During Parasitic Diseases. Front Cell Infect Microbiol 2019;9:401. https://doi.org/10.3389/fcimb.2019.00401.

Banerjee A, Bhattacharya P, Dagur PK, Karmakar S, Ismail N, Joshi AB, et al. Live Attenuated Leishmania donovani Centrin Gene-Deleted Parasites Induce IL-23-Dependent IL-17-Protective Immune Response against Visceral Leishmaniasis in a Murine Model. J Immunol Baltim Md 1950 2018;200:163–76. https://doi.org/10.4049/jimmunol.1700674.

Zohar Y, Wildbaum G, Novak R, Salzman AL, Thelen M, Alon R, et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J Clin Invest 2014;124:2009–22. https://doi.org/10.1172/JCI71951.

Foley JF. Polyfunctional T Cells. Sci Signal 2012;5:ec42–ec42. https://doi.org/10.1126/scisignal.2002929.

Lewinsohn DA, Lewinsohn DM, Scriba TJ. Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination. Front Immunol 2017;8:1262. https://doi.org/10.3389/fimmu.2017.01262.

Burel JG, Apte SH, Groves PL, McCarthy JS, Doolan DL. Polyfunctional and IFN-γ monofunctional human CD4+ T cell populations are molecularly distinct. JCI Insight 2017;2:e87499. https://doi.org/10.1172/jci.insight.87499.

Macedo ABB, Sánchez-Arcila JC, Schubach AO, Mendonça SCF, Marin-Dos-Santos A, Madeira M de F, et al. Multifunctional CD4+T cells in patients with American cutaneous leishmaniasis. Clin Exp Immunol 2012;167:505–13. https://doi.org/10.1111/j.1365-2249.2011.04536.x.

Han Q, Bagheri N, Bradshaw EM, Hafler DA, Lauffenburger DA, Love JC. Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci 2012;109:1607. https://doi.org/10.1073/pnas.1117194109.

Borges da Silva H, Fonseca R, Alvarez JM, D’Império Lima MR. IFN-γ Priming Effects on the Maintenance of Effector Memory CD4(+) T Cells and on Phagocyte Function: Evidences from Infectious Diseases. J Immunol Res 2015;2015:202816. https://doi.org/10.1155/2015/202816.

Stäger S, Rafati S. CD8(+) T cells in leishmania infections: friends or foes? Front Immunol 2012;3:5. https://doi.org/10.3389/fimmu.2012.00005.